Investigating how a specific RNA modification affects amyloid-β levels in Alzheimer's disease
Dysregulation of amyloid-β metabolism by impaired METTL3-m6A signaling in Alzheimer's Disease
This study is looking at how a specific chemical change in a protein affects the buildup of a harmful substance in the brains of people with Alzheimer's, hoping to find new ways to help treat the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11192296 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of N6-methyladenosine (m6A) methylation in the metabolism of amyloid-β (Aβ), a protein that accumulates in the brains of Alzheimer's disease patients. The study aims to explore how reduced levels of METTL3, an enzyme responsible for m6A modification, influence the production and degradation of Aβ, potentially leading to increased amyloid plaque formation. By examining the genetic pathways involved in Aβ metabolism, the researchers hope to uncover new insights into the mechanisms of Alzheimer's disease and identify potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those showing early signs of cognitive decline.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to amyloid-β accumulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for reducing amyloid-β accumulation, potentially slowing the progression of Alzheimer's disease.
How similar studies have performed: While the role of m6A methylation in neurodegenerative diseases is being explored, this specific investigation into its impact on Aβ metabolism in Alzheimer's disease is relatively novel.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Zhao, Fanpeng — Case Western Reserve University
- Study coordinator: Zhao, Fanpeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.